Cogenzia

Cogenzia is a private specialty pharmaceutical company primarily focused on identifying and developing high-potential therapeutic candidates for oncology and autoimmune disorders. The company is notably recognized for its role in the early-stage development and subsequent licensing of key assets, such as the CD20-targeting monoclonal antibody ublituximab, to TG Therapeutics. Led by experienced biotechnology executives, Cogenzia operates as a strategic entity that bridges early discovery with clinical-stage partnerships. Its portfolio has historically centered on glycoengineered antibodies and targeted small molecules designed to improve efficacy and safety profiles in B-cell malignancies and inflammatory conditions. The company's business model emphasizes the acquisition of promising intellectual property and the advancement of these programs through critical development milestones.